相关实验视频
Updated: Jan 16, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
95.7K
在患有先天性超胰岛素症的患者中,KCNJ11的读透变异
Erika Uehara1,2, Keiichi Sugihara3, Ikue Hata3
1Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
概括
先天性高胰岛素症 (CHI) 可能是由罕见的KCNJ11基因变异引起的. 发现了一种新的KCNJ11变异,这表明了这种罕见遗传疾病的新机制.
科学领域:
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 先天性高胰岛素症 (CHI) 是持续新生儿和婴儿低血糖症的重要原因.
- KCNJ11基因是已知的CHI的主要遗传决定因素.
- 之前的研究发现了有限的KCNJ11变异,仅报告了一种读透变异,其致病性仍未得到证实.
研究的目的:
- 为了研究一种新型KCNJ11基因变异的致病性,该变异在患有CHI的新生儿中被发现.
- 探索单基KCNJ11读透变异在CHI病因学中的作用.
主要方法:
- 基因测序以确定KCNJ11基因中的核酸替代物.
- 分析变异性致病性和对蛋白质功能的潜在主导负面影响.
- 临床相关性与患者表现和家族病史.
主要成果:
- 在新生儿中与CHI及其父亲的KCNJ11基因中确定了两种异构核酸替代 (c.[1170C>T;1172G>T)).
- 这些变异导致了无声替代 (p.Ser390Ser) 和读透替代 (p.Ter391LeuextTer93),产生了一个突变的KCNJ11蛋白质,附有93种额外的氨基酸.
- 预计突变的KCNJ11蛋白对野生型蛋白质产生主导负面影响.
结论:
- 单基KCNJ11读透变体代表了先天性高胰岛素症的罕见原因.
- 鉴定到的KCNJ11变异可能通过主导负效应导致CHI.
- 这一发现扩大了已知的CHI遗传景观,并强调了调查读透变异的重要性.
相关概念视频
Inborn Errors of Metabolism
696
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
696
Insulin: Dosing Regimen and Adverse Effects
680
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
680
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Insulin Formulations: Types and Delivery
653
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
653

